top of page

UCB and Amgen submit FDA application for Osteoporosis drug

UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.


Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/42564/news/industry-news/ucb-amgen-fda-osteoporosis-drug/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page